Chemosensitisation of malignant melanoma by BCL2 antisense therapy

Lancet

Volumn 356, Issue 9243, 2000, Pages 1728-1733

  Jansen, B ^a   Wacheck, V ^a   Heere Ress, E ^a   Schlagbauer Wadl, H ^a   Hoeller, C ^a   Lucas, T ^a   Hoermann, M ^a   Hollenstein, U ^a   Wolff, K ^a   Pehamberger, H ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; AUGMEROSAN; DACARBAZINE; MESSENGER RNA; OBLIMERSEN; PROTEIN BCL 2; UNCLASSIFIED DRUG;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CHEMOSENSITIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEBRILE NEUTROPENIA; FEMALE; FEVER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LYMPHOCYTOPENIA; MALE; MELANOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTO ONCOGENE; SKIN METASTASIS; SURVIVAL TIME; TUMOR XENOGRAFT; WESTERN BLOTTING;

EID: 0034684471     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)03207-4     Document Type: Article

References (26)

1. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma
2. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma
3. Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice
4. Dysregulation of apoptosis in cancer
5. Accelerated disappearance of melanocytes in bcl-2-deficient mice
6. Expression of Bcl-2 family members in human melanocytes, in melanoma metastases and in melanoma cell lines
7. Bcl-2 expression in malignant melanoma and its prognostic significance
8. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma
9. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma
10. Determination of antisense phosphorothioate oligonucleotides and catabolites in biological fluids and tissue extracts using anion-exchange high-performance liquid chromatography and capillary gel electrophoresis
11. Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice
12. Bcl-2 protein expression in cutaneous malignant melanoma and benign melanocytic nevi
13. Phase I evaluation of CGP 64128A, an antisense inhibitor of protein kinase C-alpha (PKCa), in patients with refractory cancer
14. Phase I pharmacokinetic/pharmacodynamic trial of Raf-1 antisense ODN (ISIS 5132, CGP 69846A)
15. A phase I trial of G3139 (Genta, Inc), a bcl-2 antisense drug, by continuous infusion as a single agent with weekly taxol
16. BCL-2 protein is topographically restricted in tissues characterized by apoptotic cell death
17. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides
18. Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair
19. Bcl-2 deficiency in mice leads to pleiotropic abnormalities: Accelerated lymphoid cell death in thymus and spleen, polycystic kidney, hair hypopigmentation, and distorted small intestine
20. Primitive human hematopoietic precursors express Bcl-x but not Bcl-2
21. Massive cell death of immature hematopoietic cells and neurons in Bcl-x-deficient mice
22. A phase I/IIa dose-escalating trial of bcl-2 antisense (G3139) treatment by 14-day continuous intravenous infusion for patients with androgen-independent prostate cancer or other advanced solid tumour malignancies
23. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma
24. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA
25. Prognostic factors for survival of patients treated systemically for disseminated melanoma
26. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: An Eastern Cooperative Oncology Group study